NeOnc Technologies Holdings (NTHI) Q3 2025 earnings summary

Executive summary

• Focused on novel drug delivery for brain cancers, with NEO100 in Phase 2a and NEO212 in Phase 1/II trials; no approved products yet.

• Completed NASDAQ listing in March 2025, raising $11.6M via private placement and establishing an equity purchase agreement for up to $50M.

• Advanced Middle East partnerships, including a $50M strategic agreement and expanded clinical trial activities.

• Achieved significant clinical milestones, including positive NEO100 Phase 2a results and FDA clearance for NEO212 Phase II trial.

• Enhanced market visibility through media campaigns and Russell Microcap Index inclusion.

Financial highlights

• Net loss of $8.6M for Q3 2025 and $46.6M for the nine months ended September 30, 2025, compared to $2.2M and $9.6M for the same periods in 2024.

• Operating expenses rose sharply, driven by $25.96M in share-based compensation and a $11.7M advisory fee related to the NASDAQ listing.

• Cash and cash equivalents at September 30, 2025 were $1.5M, with an accumulated deficit of $97.2M.

• Financing activities provided $18.2M in the nine months ended September 30, 2025, mainly from equity sales and convertible notes.

• G&A expenses increased by 270% year-over-year, while R&D expenses decreased by 25%.

Outlook and guidance

• Expects continued significant operating losses as clinical development and commercialization efforts expand.

• Requires substantial additional funding to support ongoing operations and growth strategy; current cash is insufficient for 12 months.

• Top-line data for NEO100-01 expected in May 2026; NEO212 Phase I final cohort dosing anticipated in Q4 2025.

• Plans to finance operations through equity, debt, and potential collaborations.

• Near-term closing and funding of the $50M Quazar Investment partnership expected.